新型GLP-1/GIP双激素DA3-CH通过激活AMPK/ACC信号通路,改善了老鼠2型糖尿病
Jing Xu1,2, Peng Chen3, Dongzhi Wu4
1Department of Endocrinology, Fuzhou Second Hospital, Fuzhou 350007, Fujian Province, China.
Aging
|October 18, 2023
概括
DA3-CH是一种新型的双重激动剂,通过改善葡萄糖,脂肪代谢和减少胰腺损伤,有效治疗2型糖尿病. 它针对AMPK/ACC途径,为T2DM提供了一个新的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 占所有糖尿病病例的95%以上.
- DA3-CH是一种新型的双受体激动剂,用于葡萄糖样-1 (GLP-1) 和依赖葡萄糖的胰岛素托普多 (GIP).
- 之前没有报道DA3-CH在T2DM中的调节作用.
研究的目的:
- 在T2DM的老鼠模型中研究DA3-CH的治疗潜力.
- 阐明潜在的分子机制,特别是AMPK/ACC信号通路的参与.
主要方法:
- 通过使用高脂肪/高糖饮食和链毒素 (STZ) 诱导建立了T2DM大鼠模型.
- 基因和蛋白质表达被通过RT-PCR和西式涂抹分析.
- 使用TUNEL染色评估胰腺组织亡;量化了血糖,脂质和氧化应激标志物.
主要成果:
- DA3-CH显著改善了T2DM症状,包括降低血糖,改善血脂概况,减少胰腺组织损伤,亡和氧化应激.
- 在T2DM大鼠中,DA3-CH治疗失活了亚丁烯酸酸激活蛋白激酶 (AMPK) /乙CoA碳氧化酶 (ACC) 信号通路.
- 作为AMPK/ACC路径抑制剂的Com-C显著逆转了DA3-CH的作用.
结论:
- DA3-CH通过准AMPK/ACC信号通路,显示了改善T2DM的潜力.
- 这项研究表明,DA3-CH是T2DM预防和治疗的新型治疗候选者,可能通过对AMPK/ACC途径的调节.
更多相关视频
12:33A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
65.3K
07:44Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation
Published on: August 7, 2015
16.3K
相关概念视频
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
